Suven Pharmaceuticals Ltd. (COHANCE) Share Price Rises 5.15% Today

Suven Pharmaceuticals Ltd. traded at Rs 470.65, up 5.15% today, with a market capitalisation of Rs 17,408.18 crore as the Healthcare stock entered the session's notable gainers list.

Suven Pharmaceuticals Ltd. Share Price moved higher to Rs 470.65 on 20 August 2026, a gain of 5.15% or Rs 23.05 from the previous close of Rs 447.60. With a market capitalisation of Rs 17,408.18 crore, the stock stood out in Stock Market Today as a mid-cap Healthcare name posting a meaningful same-day price rise. The session's move also places COHANCE among Stocks in News and the day's visible market movers.

The trading pattern shows that the stock opened at Rs 451.10, stayed above the previous close, and advanced to an intraday high of Rs 472.50 before holding near that zone. The day low was Rs 448.30, indicating that the price action remained constructive after the open. The supplied data confirms the price event clearly, although it does not establish a company-specific catalyst behind today's move.

For readers tracking Suven Pharmaceuticals Ltd. Stock News, the relevance lies in both the size of the move and the market-cap context. The stock has been captured by a price-rise threshold screen for the Mid Cap category, making this more than a routine uptick. Early questions for investors are straightforward: what exactly happened in today's trade, how strong was participation, how does the company sit against Healthcare sector benchmarks, and how does its size compare with listed peers? This Univest analysis addresses those verified points without stretching beyond the available data.

Suven Pharmaceuticals Ltd. (COHANCE) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 470.65
Previous Close	Rs 447.6
Today's Change	+Rs 23.05 (+5.15%)
Day Open	Rs 451.1
Day High	Rs 472.5
Day Low	Rs 448.3
Current Volume (BSE)	76,949
BSE Traded Volume	76,949
NSE Traded Volume	5,72,333
Combined NSE + BSE Volume	6,49,282
Turnover	Rs 3.62 crore
Market Capitalisation	Rs 17,408.18 crore
Market Cap Category	Mid Cap

Suven Pharmaceuticals Ltd. (COHANCE) traded at Rs 470.65. versus the previous close of Rs 447.6, a rise of 5.15%. The stock opened at Rs 451.1, reached Rs 472.5, touched Rs 448.3. Reported volume was 76,949.

Suven Pharmaceuticals Ltd. (COHANCE) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 17,408.18 crore

Suven Pharmaceuticals Ltd. Fundamental Analysis, based strictly on the supplied data, begins with size and positioning. The company carries a market capitalisation of Rs 17,408.18 crore, which is far above the Healthcare sector benchmark median market cap of Rs 135.91 crore and the benchmark average of Rs 467.67 crore across 196 companies in the same sector. That gap does not by itself signal quality, but it does show that the company is much larger than the typical name in the benchmark set used here.

Because no company-specific profitability, leverage, cash-generation or valuation multiples were supplied for Suven Pharmaceuticals Ltd., today's fundamental context has to be read through what is available with discipline: market value, sector framework, and peer set. In practical terms, this means investor attention is currently being supported more by the stock's size, listing visibility and today's price action than by a fresh batch of disclosed ratio data within this dataset. That distinction matters in Univest stock analysis because a strong day move and a complete fundamental case are not always the same thing.

The stock's current price of Rs 470.65 against a Rs 17,408.18 crore market cap suggests that market participants are dealing with a company that is not a micro or narrowly traded small-cap counter. Instead, it is a mid-cap Healthcare stock large enough to be tracked in broader Share Market Today conversations. The day's 5.15% share price gain therefore becomes notable not merely in percentage terms but also because it happened in a company of this size.

For investors reading Suven Pharmaceuticals Ltd. Financial Results searches or Suven Pharmaceuticals Ltd. Earnings queries, the key limitation of today's data-driven view is simple: the move is confirmed, the market size is confirmed, but the supplied dataset does not establish a company-specific operating trigger. That leaves valuation and profitability benchmarking through the sector and peer sections as the most useful verified framework for interpretation. Univest therefore shifts the lens from the tape to comparative context rather than speculation.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Benchmark Median P/E	26.32x
Benchmark Average P/E	61.3x
Benchmark P/E Range	2.76x to 1,607.56x
Benchmark Median P/B	1.9x
Benchmark Median ROE	11.12%
Benchmark Median ROCE	13.35%
Company Market Capitalisation	Rs 17,408.18 crore
Benchmark Median Market Cap	Rs 135.91 crore

Suven Pharmaceuticals Ltd. (COHANCE) is classified under sector: Healthcare.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Suven Pharmaceuticals Ltd. operates within the Healthcare sector, and the benchmark snapshot offers a useful frame for understanding where today's move sits in a broader listed universe. The benchmark here covers 196 companies in the same sector, giving a wide sample for comparing valuation dispersion, profitability and company size without relying on generic sector commentary.

The Healthcare benchmark shows a median P/E of 26.32 and an average P/E of 61.30 across 157 companies, with a very wide range from 2.76 to 1,607.56. That spread indicates that sector valuations are highly dispersed, so single stock interpretation needs care. On price-to-book, the median is 1.90 and the average is 2.61 across 195 companies, with values ranging from -13.33 to 16.47. Profitability also varies meaningfully: median ROE stands at 11.12% and average ROE at 15.66%, while median ROCE is 13.35% and average ROCE is 17.87% across 195 companies.

What stands out most clearly for Suven Pharmaceuticals Ltd. Market Cap is its scale relative to this benchmark universe. At Rs 17,408.18 crore, the company sits far above the benchmark maximum market cap figure of Rs 3,012.78 crore listed in the supplied comparison set, and dramatically above both the median and average for the wider Healthcare sample. That does not automatically imply premium valuation or superior quality, but it does show that the stock occupies a much larger capitalisation bracket than the median sector name.

Sector analysis is therefore useful in two ways. First, it shows that Healthcare as a listed space contains a wide mix of valuation and profitability profiles. Second, it highlights that Suven Pharmaceuticals Ltd. Share Price is being watched in the context of a company whose market value is substantially larger than the benchmark norms supplied here. In Univest coverage, that makes today's rise notable not only as price action but also as a move in a comparatively large Healthcare counter.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Ind-Swift Laboratories Ltd.	INDSWFTLAB	3,012.78	48.9	1.87	-0.78	8.31
Hikal Ltd.	HIKAL	2,679.94	0	2.22	15.22	16.15
Dishman Carbogen Amcis Ltd.	DCAL	2,648.85	167.12	0.41	-2.89	-0.26
Solara Active Pharma Sciences Ltd.	SOLARA	2,641.96	0	2.08	17.23	15.34
Beta Drugs Ltd.	BETA	2,610.72	64.32	10.17	18.65	22.17

Suven Pharmaceuticals Ltd. (COHANCE) has a market capitalisation of Rs 17,408.18 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Peer comparison helps convert a single-day move into a relative market context. The supplied peer list is dominated by Healthcare companies, especially Pharmaceuticals & Drugs names, with one Hospital & Healthcare Services company also included. Against these peers, Suven Pharmaceuticals Ltd. stands out most obviously on scale: its market capitalisation of Rs 17,408.18 crore is materially larger than Ind-Swift Laboratories at Rs 3,012.78 crore, Hikal at Rs 2,679.94 crore, Dishman Carbogen Amcis at Rs 2,648.85 crore, Solara Active Pharma Sciences at Rs 2,641.96 crore and Beta Drugs at Rs 2,610.72 crore.

Among peers with disclosed P/E ratios, valuation readings are mixed. Ind-Swift Laboratories trades at 48.90, Dishman Carbogen Amcis at 167.12, Beta Drugs at 64.32, Dr Agarwals Eye Hospital at 33.71, Venus Remedies at 20.40, Sai Parenteral's at 167.39 and Fredun Pharmaceuticals at 53.77. Since no P/E has been supplied for Suven Pharmaceuticals Ltd., a direct valuation ranking cannot be made from this dataset. Even so, the peer set shows that Healthcare names in this universe trade across a broad band of earnings multiples, reinforcing the need for caution when reading a single-day price rise as a valuation statement.

Profitability among peers is equally varied. ROE ranges from -2.89% for Dishman Carbogen Amcis and -0.78% for Ind-Swift Laboratories to 36.29% for Dr Agarwals Eye Hospital, while ROCE spans from -0.26% to 42.40%. Beta Drugs reports ROE of 18.65% and ROCE of 22.17%, Hikal shows 15.22% and 16.15%, Solara reports 17.23% and 15.34%, and Venus Remedies stands at 9.85% and 7.89%.

For Suven Pharmaceuticals Ltd. Stock Analysis, the peer takeaway is straightforward: the company is much larger than the supplied listed comparables, while the peer group itself displays substantial variation in valuation and return ratios. That makes today's Suven Pharmaceuticals Ltd. Share Price Rise important from a market-movement perspective, but it also means that a clean relative valuation conclusion cannot be drawn without additional company-specific multiples in the dataset. Univest readers should therefore treat peer data as context on scale and sector dispersion rather than a definitive verdict.

Why Investors Are Watching Suven Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd. has moved into focus because today's market action combined a meaningful percentage gain with a sizeable market capitalisation and solid trading participation. In a session where investors screen for Top Gainers Today and Stocks Rising Today, this stock qualified as a notable Mid Cap mover. The supplied data confirms the move itself, the traded range and the cross-exchange volume footprint.

• Verified price action: the stock rose 5.15% from Rs 447.60 to Rs 470.65, with an intraday high of Rs 472.50.
• Intraday range: trading stayed between Rs 448.30 and Rs 472.50 after opening at Rs 451.10.
• Volume footprint: total traded volume reached 6,49,282 shares, including 5,72,333 on NSE and 76,949 on BSE.
• Market size: market capitalisation stands at Rs 17,408.18 crore, making this a sizeable Healthcare mid-cap name.
• Sector context: the stock belongs to a Healthcare universe where benchmark valuations and profitability vary widely across 196 companies.
• Peer positioning: the company is much larger in market-cap terms than the supplied peer list.

What should investors monitor next? The key points are whether Suven Pharmaceuticals Ltd. Share Price holds close to the upper end of today's range, whether turnover and total volume remain elevated in upcoming sessions, and whether future disclosures provide company-specific valuation or profitability metrics that can be compared more directly with the Healthcare benchmark and peers. That is the disciplined way to track momentum without turning a single-day move into a forecast.

About Suven Pharmaceuticals Ltd.

Based on the supplied dataset, Suven Pharmaceuticals Ltd. is a listed Healthcare company tracked under the symbol COHANCE. The company is being analysed here in the context of the Healthcare sector and a peer universe that is largely composed of Pharmaceuticals & Drugs businesses, along with selected related Healthcare companies. That framing places the stock within one of the Indian market's most actively watched defensive and research-sensitive sectors.

The available comparison set shows that companies around this space can differ sharply in valuation, return ratios and size. Some peers trade at relatively moderate P/E multiples, while others carry very high multiples or do not have a supplied P/E in the current dataset. Return ratios also vary from negative ROE and ROCE in certain cases to very strong profitability in others. This tells investors that Healthcare is not a uniform block; it is a sector where company-specific execution and financial profile can create very different market outcomes.

What is clear from the available numbers is that Suven Pharmaceuticals Ltd. is materially larger by market capitalisation than the peer names listed in the supplied snapshot. That makes Suven Pharmaceuticals Ltd. Share News relevant not only for traders tracking short-term market moves but also for investors who follow larger listed Healthcare names for sector signals. Univest therefore treats the company as an important stock to watch within its peer set, particularly when a price rise of this size appears in a single trading session.

Track Suven Pharmaceuticals Ltd. Share Price on Univest

Use Suven Pharmaceuticals Ltd. (COHANCE) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Readers following Suven Pharmaceuticals Ltd. Share Price can use Univest to track live price moves, daily change, market capitalisation, 52-week levels, technical indicators when available, valuation ratios when disclosed, and broader market insights around the stock. For users searching Suven Pharmaceuticals Ltd. Share Price Live, Suven Pharmaceuticals Ltd. Latest News or Suven Pharmaceuticals Ltd. Shareholding Pattern, Univest helps bring price data and research context into one place.

Because today's move has pushed the stock into the spotlight, it is especially useful to watch how Suven Pharmaceuticals Ltd. Share Price Today behaves relative to intraday highs, turnover and broader Healthcare sector screens. Univest coverage is designed to keep that tracking factual, current and linked to verified market data rather than speculation.

Frequently Asked Questions

What is Suven Pharmaceuticals Ltd. Share Price today?

Ans. Suven Pharmaceuticals Ltd. Share Price today is Rs 470.65. The stock was up Rs 23.05, or 5.15%, from the previous close of Rs 447.60, making it one of the more visible Healthcare gainers in today's session.

Why is Suven Pharmaceuticals Ltd. rising today?

Ans. The supplied data confirms that the stock rose 5.15% in today's trade and qualified under a price-rise screen for its Mid Cap category. However, the dataset establishes the move itself rather than a company-specific catalyst behind it.

What were the day's open, high and low for COHANCE?

Ans. COHANCE opened at Rs 451.10, touched an intraday high of Rs 472.50 and a low of Rs 448.30. The current price of Rs 470.65 leaves the stock trading close to the upper end of today's range.

How much market capitalisation does Suven Pharmaceuticals Ltd. have?

Ans. Suven Pharmaceuticals Ltd. has a market capitalisation of Rs 17,408.18 crore. That makes it a mid-cap stock in this workflow and also far larger than the benchmark median Healthcare company in the supplied sector snapshot.

How much volume was traded in Suven Pharmaceuticals Ltd. today?

Ans. Total traded volume stood at 6,49,282 shares. Of this, 76,949 shares were reported on BSE and 5,72,333 shares on NSE, while the reported turnover figure in the dataset was Rs 3.62 crore.

Is Suven Pharmaceuticals Ltd. in the Healthcare sector?

Ans. Yes, Suven Pharmaceuticals Ltd. is classified in the Healthcare sector in the supplied data. Its peer and benchmark context in this article is therefore drawn from the same sector rather than from a broader market sample.

How does Suven Pharmaceuticals Ltd. compare with Healthcare sector size benchmarks?

Ans. At Rs 17,408.18 crore, the company's market capitalisation is well above the Healthcare benchmark median of Rs 135.91 crore and average of Rs 467.67 crore across 196 companies in the supplied sector universe.

Which peers are included in the comparison for Suven Pharmaceuticals Ltd.?

Ans. The supplied peer set includes Ind-Swift Laboratories, Hikal, Dishman Carbogen Amcis, Solara Active Pharma Sciences, Beta Drugs, Dr Agarwals Eye Hospital, Panacea Biotec, Venus Remedies, Sai Parenteral's and Fredun Pharmaceuticals.

Does today's move make Suven Pharmaceuticals Ltd. a top gainer?

Ans. The stock's 5.15% one-day rise puts it among today's notable gainers in this workflow's screening context. It was captured under a same-day price-rise event for a Mid Cap stock, not a 52-week high event.

What should investors monitor after this Suven Pharmaceuticals Ltd. Share Price rise?

Ans. Investors can monitor whether the stock sustains levels near today's high of Rs 472.50, whether traded volume remains active after 6,49,282 shares today, and how future company disclosures improve direct peer and sector comparisons.